Clinical characteristics and early outcomes in patients with COVID-19 treated with tocilizumab at a United States academic center

Competing Interest Statement

JBP reports research support outside the submitted work from Gilead Sciences and the World Health Organization, and non-financial support from Abbott Laboratories. CLG has received research support outside the submitted work from Viiv Healthcare and Gilead Sciences. SSC reports research support outside of the submitted work from Biomarck Pharmaceuticals.

Funding Statement

The authors report no designated funding for the project. CAR and CEM receive training support from the University of North Carolina at Chapel Hill Medical Scientist Training Program. CAR additionally receives training support from the National Institutes of Health MD/PhD Partnership Program.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by the UNC Institutional Review Board

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes